News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,590 Results
Type
Article (43719)
Company Profile (474)
Press Release (694385)
Multimedia
Podcasts (123)
Webinars (20)
Section
Business (209330)
Career Advice (2045)
Deals (36153)
Drug Delivery (119)
Drug Development (83977)
Employer Resources (174)
FDA (16697)
Job Trends (15192)
News (354188)
Policy (33281)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2658)
Accelerated approval (36)
Adcomms (28)
Allergies (146)
Alliances (51112)
ALS (178)
Alzheimer's disease (1731)
Antibody-drug conjugate (ADC) (334)
Approvals (16940)
Artificial intelligence (549)
Autoimmune disease (165)
Automation (41)
Bankruptcy (373)
Best Places to Work (11842)
BIOSECURE Act (20)
Biosimilars (195)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (61)
Breast cancer (655)
Cancer (4968)
Cardiovascular disease (419)
Career advice (1729)
Career pathing (38)
CAR-T (294)
CDC (46)
Celiac Disease (2)
Cell therapy (786)
Cervical cancer (36)
Clinical research (71487)
Collaboration (1811)
Company closure (4)
Compensation (1188)
Complete response letters (66)
COVID-19 (2773)
CRISPR (101)
C-suite (895)
Cystic fibrosis (152)
Data (6359)
Decentralized trials (2)
Denatured (39)
Depression (145)
Diabetes (507)
Diagnostics (6760)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (270)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (246)
Earnings (91501)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121076)
Executive appointments (1013)
FDA (19874)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1542)
Gene editing (217)
Generative AI (45)
Gene therapy (651)
GLP-1 (1011)
Government (4761)
Grass and pollen (6)
Guidances (385)
Healthcare (19211)
HIV (62)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (278)
Immuno-oncology (62)
Indications (115)
Infectious disease (3051)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (120)
Intellectual property (257)
Interviews (316)
IPO (16935)
IRA (53)
Job creations (3714)
Job search strategy (1444)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8028)
Liver cancer (93)
Longevity (14)
Lung cancer (670)
Lymphoma (385)
Machine learning (43)
Management (59)
Manufacturing (820)
MASH (172)
Medical device (13927)
Medtech (13981)
Mergers & acquisitions (20303)
Metabolic disorders (1326)
Multiple sclerosis (168)
NASH (19)
Neurodegenerative disease (342)
Neuropsychiatric disorders (97)
Neuroscience (3033)
Neurotech (1)
NextGen: Class of 2026 (6771)
Non-profit (4587)
Now hiring (67)
Obesity (635)
Opinion (286)
Ovarian cancer (168)
Pain (205)
Pancreatic cancer (234)
Parkinson's disease (296)
Partnered (34)
Patents (505)
Patient recruitment (508)
Peanut (57)
People (60343)
Pharmaceutical (86)
Pharmacy benefit managers (30)
Phase 1 (22484)
Phase 2 (31517)
Phase 3 (23298)
Pipeline (5436)
Policy (299)
Postmarket research (2602)
Preclinical (9610)
Press Release (67)
Prostate cancer (247)
Psychedelics (56)
Radiopharmaceuticals (302)
Rare diseases (902)
Real estate (6065)
Recruiting (71)
Regulatory (25042)
Reports (53)
Research institute (2488)
Resumes & cover letters (355)
Rett syndrome (27)
RNA editing (21)
RSV (78)
Schizophrenia (156)
Series A (255)
Series B (202)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (18)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1039)
Venture capital (96)
Weight loss (411)
Women's health (94)
Worklife (19)
Date
Today (188)
Last 7 days (566)
Last 30 days (2282)
Last 365 days (30794)
2026 (3778)
2025 (31063)
2024 (36299)
2023 (41015)
2022 (52277)
2021 (56764)
2020 (54922)
2019 (47417)
2018 (35698)
2017 (33025)
2016 (32348)
2015 (38398)
2014 (32189)
2013 (27111)
2012 (29220)
2011 (29863)
2010 (27995)
Location
Africa (755)
Alabama (89)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40716)
Australia (6765)
California (11559)
Canada (3324)
China (1145)
Colorado (489)
Connecticut (500)
Delaware (342)
Europe (89290)
Florida (1707)
Georgia (361)
Hawaii (3)
Idaho (61)
Illinois (890)
India (68)
Indiana (529)
Iowa (24)
Japan (440)
Kansas (131)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1409)
Massachusetts (8389)
Michigan (329)
Minnesota (642)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3073)
New Mexico (31)
New York (3027)
North Carolina (1544)
North Dakota (9)
Northern California (5628)
Ohio (339)
Oklahoma (21)
Oregon (45)
Pennsylvania (2314)
Puerto Rico (24)
Rhode Island (49)
South America (1123)
South Carolina (66)
South Dakota (1)
Southern California (4485)
Tennessee (176)
Texas (1777)
United States (41102)
Utah (343)
Vermont (1)
Virginia (271)
Washington D.C. (82)
Washington State (961)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
738,590 Results for "dice therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
October 19, 2025
·
4 min read
Deals
Lilly Completes Acquisition of DICE Therapeutics
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of DICE Therapeutics, Inc. (NASDAQ: DICE).
August 9, 2023
·
4 min read
Deals
Lilly to Acquire DICE Therapeutics to Advance Innovation in Immunology
Eli Lilly and Company and DICE Therapeutics, Inc. announced a definitive agreement for Lilly to acquire DICE.
June 20, 2023
·
9 min read
Biotech Bay
DICE Therapeutics to Participate in the Bank of America Securities 2023 Healthcare Conference
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023 at 3:00 p.m. PT / 6:00 p.m. ET.
May 3, 2023
·
1 min read
Biotech Bay
DICE Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today announced management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30, 2023 at 4:00 p.m. ET.
March 23, 2023
·
1 min read
Business
DICE Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights
DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2022 and highlighted recent corporate achievements.
March 15, 2023
·
8 min read
Press Releases
Sale of Intellectual Property – Mythic Therapeutics Inc.
December 23, 2025
·
1 min read
Biotech Bay
DICE Therapeutics to Host R&D Investor Event on Tuesday, June 20, 2023
DICE Therapeutics, Inc. announced that management will host a research & development day on Tuesday, June 20, 2023 from 12:00 p.m. – 2:30 p.m. ET in New York, NY.
June 13, 2023
·
1 min read
Press Releases
Sentynl Therapeutics Inc. Announces FDA Approval of ZYCUBO® (copper histidinate)
January 13, 2026
·
9 min read
Business
DICE Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights
DICE Therapeutics, Inc., a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate achievements.
May 11, 2023
·
8 min read
1 of 73,859
Next
